New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 29, 2010
11:16 EDTCSTR, BCSI, DELL, WDC, LLY, MNKDOn The Fly: Rumor Buzz
Market speculation today includes takeover chatter involving Coinstar (CSTR)...Blue Coat Systems (BCSI) advances about 4.9% and is again the subject of an unconfirmed takeover rumor. Dell (DELL) has previously been mentioned as a possible suitor...Western Digital Corp. (WDC) is up almost 3.5% on renewed takeover speculation...Unconfirmed is a rumor that Eli Lilly & Co. (LLY) is readying a $12.50 bid for MannKind Corp. (MNKD), up 2.9%.
News For CSTR;BCSI;DELL;WDC;LLY;MNKD From The Last 14 Days
Check below for free stories on CSTR;BCSI;DELL;WDC;LLY;MNKD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 18, 2014
11:47 EDTMNKDStocks with call strike movement; BBRY MNKD
Subscribe for More Information
07:25 EDTWDCWestern Digital has positive read through from Seagate results, says RBC Capital
Subscribe for More Information
July 17, 2014
17:56 EDTWDCWestern Digital down 1.2% after peer Seagate reports Q4 results
July 16, 2014
11:53 EDTMNKDStocks with call strike movement; MNKD SUNE
MannKind (MNKD) January 17 call option implied volatility increased 6% to 79, SunEdison (SUNE) October 28 call option implied volatility increased 3% to 58 according to IVolatility.
10:00 EDTWDCOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:15 EDTWDCWestern Digital upgraded at RW Baird
Subscribe for More Information
08:21 EDTLLYEli Lilly reports beta-amyloid imaging results in Alzheimer's Disease
Subscribe for More Information
07:05 EDTLLYEli Lilly and Immunocore partner to develop cancel therapies
Eli Lilly and Immunocore today announced they have entered into a co-discovery and co-development collaboration to research and potentially develop novel T cell-based cancer therapies. Immunocore will receive an upfront fee of $15M per program for the discovery of novel ImmTACs against jointly-selected cancer targets in order to generate preclinical candidate packages. If Lilly accepts a preclinical candidate package to develop and potentially commercialize, Immunocore will receive an opt-in fee of $10M and will have an option to continue co-development with Lilly on a cost-sharing and profit-sharing basis. If Immunocore does not exercise its option, it will be entitled to potential future significant milestone and royalty payments.
06:06 EDTWDCWestern Digital upgraded to Outperform from Neutral at RW Baird
July 15, 2014
11:13 EDTLLYPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
10:00 EDTWDCOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:06 EDTLLYAnthera Pharmaceuticals to host conference call
Management discusses the acquisition of Sollpura (liprotamase) for Exocrine Pancreatic Insufficiency from Eli Lilly & Company on a conference call to be held on July 15 at 8:30 am.
07:35 EDTLLYPerrigo potential buyers list could be limited, says Jefferies
After Globes reported that Perrigo retained an investment bank to assist with a potential merger, Jefferies says the list of potential buyers could be limited since the store brand business is fundamentally a high volume, lower margin model. The firm notes U.S. companies that currently do not have large over-the-counter divisions include Bristol-Myers (BMY), Eli Lilly (LLY) and Merck (MRK). Jefferies views the merger speculation surrounding Perrigo as not surprising given the company's strong long-term fundamentals and attractive Irish domicile. It has a Buy rating on the stock with a $160 price target.
05:47 EDTLLYEli Lilly announces results from five datasets from Alzheimer's disease study
Eli Lilly announced results from an analyses of five datasets evaluating the relationship between cognitive and functional impairment in patients with mild Alzheimer's disease in the natural course of the disease. Analysis findings demonstrate that cognitive deficits predict subsequent functional deficits and suggest that cognitive decline experienced by patients is followed by an observable related decline in function, consistent with previously proposed hypotheses. These data were presented today at the Alzheimer's Association International Conference 2014 in Copenhagen, Denmark as part of the featured research session, "Statistics in the Race against Alzheimer's Disease." Hong Liu-Seifert, Ph.D., study research advisor at Eli Lilly stated, "These data support the concept that decline in cognition is later reflected in changes in function. This suggests that with treatments that target the underlying neuropathology of disease, effects on function may take longer to observe in clinical studies. Currently available scales were not developed to assess subtle functional changes or treatment effects on these deficits in patients with early or mild Alzheimer's disease, and there is debate as to how much variability exists in these scales globally. Therefore, we support discussion of alternative ways to demonstrate clinical meaningfulness in early or mild Alzheimer's disease."
July 14, 2014
16:45 EDTLLYAnthera Pharmaceuticals acquires Sollpura from Eli Lilly
Subscribe for More Information
16:40 EDTWDCWestern Digital initiated with a Positive at Susquehanna
Subscribe for More Information
11:21 EDTWDCWestern Digital added to short-term buy list at Deutsche Bank
Subscribe for More Information
08:34 EDTWDCPC market stability could be short-lived, Reuters says
Subscribe for More Information
07:23 EDTLLYAlzheimer's Association to hold a conference
Subscribe for More Information
06:59 EDTWDCWestern Digital price target raised to $118 from $100 at Deutsche Bank
Deutsche Bank raised its price target for Western Digital shares to $118 on expectations PC market strength will continue and that enterprise will recover in the second half of 2014. Deutsche expects Western Digital to report June quarter results above guidance due to market share gains and it keeps a Buy rating on the stock.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use